Compare TNXP & LMNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | LMNR |
|---|---|---|
| Founded | 2007 | 1893 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 235.0M |
| IPO Year | 2008 | 2005 |
| Metric | TNXP | LMNR |
|---|---|---|
| Price | $13.47 | $13.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 425.9K | 56.2K |
| Earning Date | 05-11-2026 | 06-08-2026 |
| Dividend Yield | N/A | ★ 2.37% |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $159,723,000.00 |
| Revenue This Year | $558.11 | N/A |
| Revenue Next Year | $38.29 | $13.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $9.40 | $11.67 |
| 52 Week High | $34.00 | $16.44 |
| Indicator | TNXP | LMNR |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 60.92 |
| Support Level | $11.98 | $13.87 |
| Resistance Level | $13.36 | $14.21 |
| Average True Range (ATR) | 0.79 | 0.26 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 60.55 | 68.00 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.